Torrent Pharmaceuticals has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) with Voluntary Action Indicated (VAI) classification for its manufacturing facility located at Indrad, Gujarat. The inspection has now been successfully closed by the USFDA. The inspection was conducted from June 03, 2024 to June 12, 2024. 

Torrent Pharmaceuticals is flagship company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.